Horizon Pharma Inc Receives a Hold from Mizuho Securities

By Ryan Adsit

In a report released today, Irina Rivkind Koffler from Mizuho Securities reiterated a Hold rating on Horizon Pharma Inc (NASDAQ: HZNP). The company’s shares opened today at $13.29.

According to TipRanks.com, Koffler is a 5-star analyst with an average return of 15.1% and a 49.5% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Synergy Pharmaceuticals Inc, Apricus Biosciences Inc, and Sucampo Pharmaceuticals.

Horizon Pharma Inc has an analyst consensus of Strong Buy, with a price target consensus of $17.86.

The company has a one year high of $21.98 and a one year low of $9.45. Currently, Horizon Pharma Inc has an average volume of 4.27M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Horizon Pharma Plc engages in the research, development, and market of pharmaceutical products. Its medicines intend to treat arthritis, inflammation, and orphan diseases. It distributes under the following brands: Actimmune, Buphenyl, Duexis, Krystexxa, Migergot, Pennsaid, Ravicti, Rayos, and Vimovo.